3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
6
Breast
3
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Colorectal Neoplasms
3
Neoplasms
2
Lung Neoplasms
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Melanoma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Esophageal Squamous Cell Carcinoma
1
EGFR-mutant Non-small Cell Lung Cancer
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
42
Carboplatin
24
Cyclophosphamide
20
Paclitaxel
19
Nivolumab
17
Cisplatin
15
fludarabine
14
Gemcitabine
12
aldesleukin
10
Docetaxel
10
Bevacizumab
9
Magnetic Resonance Spectroscopy
8
Trastuzumab
7
Specimen Handling
7
Drug Therapy
7
Pemetrexed
6
Oxaliplatin
6
Ipilimumab
6
Interleukin-2
6
Fluorouracil
6
Cetuximab
6
Blood Specimen Collection
6
sargramostim
5
pegfilgrastim
5
avelumab
5
Topotecan
5
Taxes
5
Irinotecan
5
palbociclib
4
durvalumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
ribociclib
×
Thoracic
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts